Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022–2023: A Prospective Cohort Study
Authors:
- Elizabeth B WhiteEWElizabeth B White
- Lauren GrantLGLauren Grant
- Josephine MakJMJosephine Mak
- Lauren OlshoLOLauren Olsho
- Laura J EdwardsLELaura J Edwards
- Allison NalewayANAllison Naleway
- Jefferey L BurgessJBJefferey L Burgess
- Harmony TynerHTHarmony Tyner
- Manjusha GaglaniMGManjusha Gaglani
- Karen LutrickKLKaren Lutrick
- Alberto Caban-MartinezAlberto Caban-Martinez
- 24 October 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (4) , 893-900
Abstract
Background: Previous estimates of vaccine effectiveness (VE) against asymptomatic influenza virus infection based on seroconversion have varied widely and may be biased. We estimated 2022–2023 influenza VE against illness and asymptomatic infection in a prospective cohort. Methods: In the HEROES-RECOVER cohort, adults at increased occupational risk of influenza exposure across 7 US sites provided weekly symptom reports and nasal swabs for reverse transcription–polymerase chain reaction (RT-PCR) influenza testing. Laboratory-confirmed influenza virus infections were classified as symptomatic (≥1 symptom) or asymptomatic during the week of testing. Participants reported demographic information and vaccination through surveys; most sites verified vaccination through medical record and immunization registry review. Person-time was calculated as days from the site-specific influenza season start (September–October 2022) through date of infection, study withdrawal, or season end (May 2023). We compared influenza incidence among vaccinated versus unvaccinated participants overall, by symptom status, and by influenza A subtype, using Cox proportional hazards regression adjusted for site and occupation. We estimated VE as (1 − adjusted hazard ratio) × 100%. Results: In total, 269 of 3785 (7.1%) participants had laboratory-confirmed influenza, including 263 (98%) influenza A virus infections and 201 (75%) symptomatic illnesses. Incidence of laboratory-confirmed influenza illness among vaccinated versus unvaccinated participants was 23.7 and 33.2 episodes per 100 000 person-days, respectively (VE: 38%; 95% CI: 15%–55%). Incidence of asymptomatic influenza virus infection was 8.0 versus 11.6 per 100 000 (VE: 13%; 95% CI: −47%, 49%). Conclusions: Vaccination reduced incidence of symptomatic but not asymptomatic influenza virus infection, suggesting that influenza vaccination attenuates progression from infection to illness.Keywords
Funding Information
- National Center for Immunization and Respiratory Diseases
- Centers for Disease Control and Prevention
- Marshfield Clinic Research Institute
- University of Arizona
- Abt Global
This publication has 24 references indexed in Scilit:
- The role of asymptomatic infections in influenza transmission: what do we really knowThe Lancet Infectious Diseases, 2023
- Vaccine Effectiveness Against Influenza A–Associated Hospitalization, Organ Failure, and Death: United States, 2022–2023Clinical Infectious Diseases, 2023
- Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023The Journal of Infectious Diseases, 2023
- Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA ProjectJournal of Epidemiology and Global Health, 2023
- COVID-19 Vaccination Perspectives and Illnesses Among Law Enforcement Officers, Firefighters, and Other First Responders in the US, January to September 2021JAMA Network Open, 2022
- SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21The Lancet Infectious Diseases, 2022
- Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in IsraelJAMA, 2022
- Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 VaccinesNew England Journal of Medicine, 2021
- Challenges in estimating influenza vaccine effectivenessExpert Review of Vaccines, 2019
- Economic burden of seasonal influenza in the United StatesVaccine, 2018